Compare NBIX & OVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | OVV |
|---|---|---|
| Founded | 1992 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 20.0B |
| IPO Year | 1996 | 2019 |
| Metric | NBIX | OVV |
|---|---|---|
| Price | $167.43 | $65.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 25 |
| Target Price | ★ $208.11 | $82.05 |
| AVG Volume (30 Days) | 1.3M | ★ 3.3M |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 1.85% |
| EPS Growth | ★ 41.95 | 13.54 |
| EPS | ★ 5.26 | 1.36 |
| Revenue | $161,626,000.00 | ★ $8,908,000,000.00 |
| Revenue This Year | $39.52 | $17.07 |
| Revenue Next Year | $14.81 | N/A |
| P/E Ratio | ★ $32.28 | $47.68 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $36.81 |
| 52 Week High | $186.12 | $73.62 |
| Indicator | NBIX | OVV |
|---|---|---|
| Relative Strength Index (RSI) | 66.05 | 49.88 |
| Support Level | $152.67 | $56.66 |
| Resistance Level | $169.57 | $67.45 |
| Average True Range (ATR) | 5.47 | 2.25 |
| MACD | 2.07 | -0.57 |
| Stochastic Oscillator | 80.70 | 44.83 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Ovintiv is an independent oil and gas producer focused on Canada's Montney and the US' Permian basins. Historically, it has been an acquisitive producer across numerous basins and plays but has divested and exited all but two. It remains an active buyer in the remaining footprint. The firm estimates that it has up to 20 and 15 years of inventory remaining in the Montney and Permian basins, respectively.